Cancer Immunotherapy Winter School Enduring materials now available Tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings, this hybrid program provides the best in cancer immunotherapy...
Advances in Cancer Immunotherapy™ is a CME- and CE-certified program for clinical oncologists, registered nurses, pharmacists and others involved in treating cancer patients with immunotherapy to learn basic immunology principles and the mechanisms and clinical applications of immunotherapy. ...
On December 7, 2020, leading experts in the cancer immunotherapy field discussed the various career paths and opportunities available in government. The recorded webinar and presentation slides are available below. Webinar Faculty: Moderator: Chris Langsdorf – Thermo Fisher...
2 attachments
On October 15, 2020, leading experts in the cancer immunotherapy field discussed strategies and tactics on how to avoid burnout from two unique perspectives a nd answered questions from attendees . The recorded webinar and presentation slides are available below. Webinar Faculty: ...
On September 1, 2020, leading experts in the cancer immunotherapy field discussed the various career paths and opportunities available in industry and answered questions from attendees . The recorded webinar and presentation slides are available below. Webinar Faculty: Moderator:...
Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with...
A Message from the President Dear Colleagues, While the global coronavirus pandemic has held our attention since March, this edition of the President’s Message will focus on the greater mission that brings us all together. June is Cancer Immunotherapy Awareness Month™ , and so, first...
Press Release Headline – Date Published SITC Publishes Clinical Practice Guideline on Immune Effector Cell-related Adverse Events – 12/18/20 SITC Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Acute Leukemia – 11/17/20 Society for Immunotherapy of Cancer...
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as...
On January 7, 2020, leading experts in cancer immunotherapy presented an overview of the publication "The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Advanced Renal Cell Carcinoma (RCC)" during a live webinar. The recorded webinar and...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us